The potential role of nemonoxacin for treatment of common infections

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 2, 2015, Pages 263-270

  Huang, Chung Hao ^a,b   Lai, Chung Chih ^a   Chen, Yen Hsu ^a,c   Hsueh, Po Ren ^d  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Acute bacterial skin and skin structure infections; Clostridium difficile infections; Community acquired pneumonia; Nemonoxacin; Sexually transmitted diseases

Indexed keywords

LEVOFLOXACIN; NEMONOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL SKIN DISEASE; CHLAMYDIA TRACHOMATIS; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY ACQUIRED PNEUMONIA; DRUG INDICATION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NEISSERIA GONORRHOEAE; PHASE 2 CLINICAL TRIAL (TOPIC); SEXUALLY TRANSMITTED DISEASE; CHLAMYDIA INFECTIONS; CLOSTRIDIUM INFECTIONS; COMMUNITY-ACQUIRED INFECTIONS; DRUG COMBINATION; GONORRHEA; PNEUMONIA, BACTERIAL; SKIN DISEASES, BACTERIAL;

ANTI-BACTERIAL AGENTS; CHLAMYDIA INFECTIONS; CLOSTRIDIUM INFECTIONS; COMMUNITY-ACQUIRED INFECTIONS; DRUG THERAPY, COMBINATION; GONORRHEA; HUMANS; LEVOFLOXACIN; PNEUMONIA, BACTERIAL; QUINOLONES; SKIN DISEASES, BACTERIAL;

EID: 84921024008     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.978288     Document Type: Article

References (48)

1. Niederman MS. Impact of antibiotic resistance on clinical outcomes and the cost of care. Crit Care Med 2001;29(4 Suppl):N114-20
2. Smith R1, Coast J. The true cost of antimicrobial resistance. BMJ 2013;346:f1493
3. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 2007;6:29-40
4. Spellberg B, Guidos R, Gilbert D, et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 2008;46:155-64
5. Redgrave LS, Sutton SB, Webber MA, Piddock LJ. Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success. Trends Microbiol 2014;22(8):438-45
6. Lin L, Chang LW, Tsai CY, et al. Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broadspectrum nonfluorinated quinolone, in healthy volunteers. Antimicrob Agents Chemother 2010;54:405-10
7. Guo B, Wu X, Zhang Y, et al. Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses. Clin Clin Drug Investig 2012;32:475-86
8. Chung DT, Tsai CY, Chen SJ, et al. Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. Antimicrob Agents Chemother 2010;54:411-17
9. Lai CC, Lee KY, Lin SW, et al. Nemonoxacin (TG-873870) for treatment of community-acquired pneumonia. Expert Rev Anti Infect Ther 2014;12:401-17
10. Poole RM. Nemonoxacin: first global approval. Drugs 2014;74:1445-53
11. Qin X, Huang H. Review of nemonoxacin with special focus on clinical development. Drug Des Devel Ther 2014;8:765-74
12. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections - full version. Clin Microbiol Infect 2011;17(Suppl 6):E1-59
13. Brown JS. Geography and the aetiology of community-acquired pneumonia. Respirology 2009;14:1068-71
14. Tsai HY, Lauderdale TL, Wang JT, et al. Updated antibiotic resistance and clinical spectrum of infections caused by Streptococcus pneumoniae in Taiwan: Emphasis on risk factors for penicillin nonsusceptibilities. J Microbiol Immunol Infect 2013;46:345-51
15. van Rensburg DJ, Perng RP, Mitha IH, et al. Efficacy and safety of nemonoxacin versus levofloxacin for communityacquired pneumonia. Antimicrob Agents Chemother 2010;54:4098-106
16. Hung YP, Lee JC, Lin HJ, et al. Clinical impact of Clostridium difficile colonization. J Microbiol Immunol Infect 2014. [Epub ahead of print]
17. Honda H, Dubberke ER. The changing epidemiology of Clostridium difficile infection. Curr Opin Gastroenterol 2014;30:54-62
18. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. New Engl J Med 2005;353:2433-41
19. Scott LJ. Fidaxomicin: a review of its use in patients with Clostridium difficile infection. Drugs 2013;73:1733-47
20. Eaton SR, Mazuski JE. Overview of severe Clostridium difficile infection. Crit Care Clin 2013;29:827-39
21. Pepin J, Valiquette L, Gagnon S, et al. Outcomes of Clostridium difficileassociated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am J Gastroenterol 2007;102:2781-8
22. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multiinstitutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. New Engl J Med 2005;353:2442-9
23. Lin YC, Huang YT, Tsai PJ, et al. Antimicrobial susceptibilities and molecular epidemiology of clinical isolates of Clostridium difficile in Taiwan. Antimicrob Cgents Chemother 2011;55:1701-5
24. Liao CH, Ko WC, Lu JJ, Hsueh PR. Characterizations of clinical isolates of Clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in Taiwan. Antimicrob Agents Chemother 2012;56:3943-9
25. Hernandez A, Sanchez MB, Martinez JL. Quinolone resistance: much more than predicted. Front Microbiol 2011;2:22
26. King C, Lin L, Leunk R, et al. In vitro resistance development to nemonoxacin for Streptococcus pneumoniae abstract 1971. Infect Dis Soc Am (IDSA) 46th Annu. Meet; American Society for Microbiology and Infectious Diseases Society of America, Washington, DC, 2008
27. Moran GJ, Abrahamian FM, Lovecchio F, Talan DA. Acute bacterial skin infections: developments since the 2005 Infectious Diseases Society of America (IDSA) guidelines. J Emerg Med 2013;44:e397-412
28. Edelsberg J, Taneja C, Zervos M, et al. Trends in US hospital admissions for skin and soft tissue infections. Emerg Infect Dis 2009;15:1516-18
29. Sader HS, Farrell DJ, Flamm RK, et al. Antimicrobial susceptibility of Gramnegative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009-2012. Int J Antimicrob Agents 2014;43:328-34
30. Sader HS, Mallick R, Kuznik A, et al. Use of in vitro susceptibility and pathogen prevalence data to model the expected clinical success rates of tigecycline and other commonly used antimicrobials for empirical treatment of complicated skin and skin-structure infections. Int J Antimicrob Agents 2007;30:514-20
31. Moran GJ, Amii RN, Abrahamian FM, Talan DA. Methicillin-resistant Staphylococcus aureus in communityacquired skin infections. Emerg Infect Dis 2005;11:928-30
32. Jenkins TC, Knepper BC, Moore SJ, et al. Antibiotic prescribing practices in a multicenter cohort of patients hospitalized for acute bacterial skin and skin structure infection. Infect Control Hosp Epidemiol 2014;35:1241-50
33. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011;52:e18-55
34. Dryden MS. Novel antibiotic treatment for skin and soft tissue infection. Curr Opin Infect Dis 2014;27:116-24
35. Lauderdale TL, Shiau YR, Lai JF, et al. Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates. Antimicrob Agents Chemother 2010;54:1338-42
36. Adam HJ, Laing NM, King CR, et al. In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. Antimicrob Agents Chemother 2009;53:4915-20
37. Chen YH, Liu CY, Lu JJ, et al. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan. J Antimicrob Chemother 2009;64:1226-9
38. Workowski KA, Berman S. Sexually transmitted diseases treatment guidelines, 2010. MMWR 2010;59(Rr-12):1-110
39. Belay T, Woart A. Cold-induced stress increases the intensity of Chlamydia genital infection in mice. J Microbiol Immunol Infect 2013;46:330-7
40. Update to CDC's Sexually transmitted diseases treatment guidelines. 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR 2012;61:590-4
41. Bolan GA, Sparling PF, Wasserheit JN. The emerging threat of untreatable gonococcal infection. New Engl J Med 2012;366:485-7
42. Unemo M, Nicholas RA. Emergence of multidrug-resistant, extensively drugresistant and untreatable gonorrhea. Future Microbiol 2012;7:1401-22
43. Kirkcaldy RD, Weinstock HS, Moore PC, et al. The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea. Clin Infect Dis 2014;59(8):1083-91
44. Chotikanatis K, Kohlhoff SA, Hammerschlag MR. In vitro activity of nemonoxacin, a novel nonfluorinated quinolone antibiotic, against Chlamydia trachomatis and Chlamydia pneumoniae. Antimicrob Agents Chemother 2014;58:1800-1
45. Gyssens IC, Dryden M, Kujath P, et al. A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections. J Antimicrob Chemother 2011;66:2632-42
46. Schaper NC, Dryden M, Kujath P, et al. Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study. Infection 2013;41:175-86
47. Lipsky BA, Berendt AR, Cornia PB, et al. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2012 54:e132-73
48. Wang QY, Li RH, Zheng LQ, Shang XH. Prevalence and antimicrobial susceptibility of Ureaplasma urealyticum and Mycoplasma hominis in female outpatients, 2009-2013. J Microbiol Immunol Infect 2014. [Epub ahead of print]